Pre-

Inclusion Criteria:

- Male or female patients ≥ 18 and ≤ 75 years of age

- Patients must have signed informed consent

- A negative pregnancy test for women with childbearing potential

- Patients with stage IIIc/IV metastatic melanoma (AJCC 6th edition) with nodal
relapse, in transit metastasis, unresectable cutaneous metastases, visceral
metastases except bone and brain metastases

- Presence of at least one lesion accessible for intra-tumoral injections of Ad-IFNg

- A negative brain scan, eliminating any brain metastases

- ECOG performance status of 0-2

- Adequate bone-marrow reserve, renal function and hepatic function as assessed by
standard laboratory criteria

- Subjects affiliated to an appropriate social security system

Inclusion Criteria:

- Negative viral serology (HIV ½, p24 Ag, HTLV 1 / 2, B and C hepatitis)

Exclusion Criteria:

- For female : the patient is pregnant or lactating or not using contraception and
proved by a negative pregnancy test

- Positive viral serology for HIV ½, p24 Ag, HTLV 1 / 2 or B and C hepatitis

- History or current manifestations of severe progressive heart disease (congestive
heart failure, coronary artery disease, uncontrolled arterial hypertension, serious
rhythm disorders or ECG signs of previous myocardial infarction)

- Any serious illness, acute or chronic, e.g. active infection requiring antibiotics,
bleeding disorders or any other condition that requires concomitant medications not
allowed during this study

- Presence of a second active cancer except in situ cervical cancer or skin carcinoma

- Intercurrent disease requiring a corticosteroid treatment or a treatment with
interferon-α

- Any autoimmune disease including active diabetes mellitus or immunodeficiency.
Vitiligo in not an exclusion criteria

- Uncontrolled thyroid dysfunction

- Concurrently participation in a biomedical research (drug or radiotherapy) within the
month preceding inclusion

- Metastatic lymph node stage alone with an indication of lymphadenectomy

- Brain or bone metastases discovered by radiological examination during the inclusion
assessment

- Surgically resectable metastases

- Ocular melanoma

- More than one line of chemotherapy for treatment of melanoma

- Chemotherapy, immunotherapy or radiotherapy within 4 weeks before baseline (6 weeks
for nitroso-ureas and mitomycin C)

- Contraindication for the use of vasopressor agents

- Treatment with molecules in pre-marketing development or whose development is
finished less than 4 weeks